Company intelligence / Profile preview
MannKind
Westlake Village, California, United Statesmannkindcorp.com ↗
- Ownership
- Public · MNKD
- Employees
- ~233
- Development stage
- Commercial
01
Overview
MannKind’s lead product, Afrezza, is an FDA-approved rapid-action inhaled insulin for adults with diabetes. The company also developed Technosphere® Technology, enabling dry-powder formulations for deep-lung drug delivery. Tyvaso DPI™, using this technology and commercialized by United Therapeutics, is approved for pulmonary arterial hypertension. Additional pipeline assets are in various stages of clinical development targeting endocrine and orphan lung diseases[2][3][4].
- Therapeutic areas
- PulmonologyEndocrinologyCardiovascularInfectious Diseases
- Modalities
- Small moleculeDevice (inhalation device)Peptides (insulin is a peptide hormone)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
United Therapeutics (Tyvaso DPI™ partnership/licensing)Immix Biopharma (collaboration on inhalable therapy for acute respiratory distress syndrome)
04
Financials
- Market cap
- $1.2B
- Total revenue
- $109.4M
- Enterprise value
- $1.4B
Beyond the preview
Go deeper on MannKind.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MannKind.